Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Rhea-AI Filing Summary

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Tonix Pharmaceuticals Holding Corp. common stock. They report control over 814,801 shares of Common Stock, including 615,025 shares issuable upon exercise of warrants, representing 4.9% of the class.

The ownership percentage is based on 15,940,801 shares of Common Stock outstanding as of May 8, 2026 and assumes exercise of the warrants held by funds managed by Sirenia. Voting and dispositive powers over these shares are reported on a shared basis, with no sole voting or dispositive power.

Key Figures

Beneficially owned shares: 814,801 shares Ownership percentage: 4.9% Shares issuable upon exercise of warrants: 615,025 shares +3 more

6 metrics

Beneficially owned shares 814,801 shares Common Stock of Tonix Pharmaceuticals reported by Sirenia and Alex Silverstein

Ownership percentage 4.9% Percent of Tonix Pharmaceuticals common stock class beneficially owned

Shares issuable upon exercise of warrants 615,025 shares Common Stock issuable upon exercise of warrants held by Sirenia-managed funds

Shares outstanding baseline 15,940,801 shares Tonix common shares outstanding as of May 8, 2026, from Form 10-Q

Shared voting power 814,801 shares Shares over which the reporting persons have shared voting power

Shared dispositive power 814,801 shares Shares over which the reporting persons have shared dispositive power

Key Terms

beneficial owner, shared voting power, shared dispositive power, warrants, +2 more

6 terms

beneficial owner regulatory

"beneficial owner of the securities reported herein"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared voting power regulatory

"Shared Voting Power 814,801.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power regulatory

"Shared Dispositive Power 814,801.00"

warrants financial

"Includes 615,025 shares of Common Stock issuable upon exercise of warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Investment Adviser regulatory

"IA, Comment for : Includes 615,025 shares of Common Stock"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

Holding Company regulatory

"HC, Comment for : Includes 615,025 shares of Common Stock"

A holding company is an organization that owns enough shares of other businesses to control them but usually does not run their day-to-day operations. Think of it as an umbrella or parent that lets investors gain exposure to several companies through one vehicle; its value depends on the performance, risks, dividends and debts of the companies it holds, so it matters for assessing diversification, control and consolidated financial health.

FAQ

What percentage of Tonix Pharmaceuticals (TNXP) does Sirenia Capital report owning?

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 4.9% of Tonix Pharmaceuticals common stock. This percentage is based on 15,940,801 shares outstanding as of May 8, 2026 and assumes exercise of certain warrants.

How many Tonix Pharmaceuticals (TNXP) shares are reported as beneficially owned?

The reporting persons disclose beneficial ownership of 814,801 Tonix Pharmaceuticals common shares. This total includes both currently held shares and shares that would be issued upon exercise of warrants held by investment funds managed by Sirenia.

How many Tonix Pharmaceuticals (TNXP) shares come from warrants held by Sirenia?

The filing states that 615,025 Tonix Pharmaceuticals common shares are issuable upon exercise of warrants. These warrants are held by investment funds managed by Sirenia and are included in the total reported beneficial ownership.

What is the share count baseline used for Sirenia’s 4.9% TNXP ownership?

The 4.9% ownership figure is calculated using 15,940,801 Tonix common shares outstanding as of May 8, 2026. This share count comes from Tonix’s Form 10-Q for the quarter ended March 31, 2026.

Do Sirenia and Alex Silverstein have sole or shared voting power over TNXP shares?

The reporting persons disclose 0 shares with sole voting or dispositive power and 814,801 shares with shared voting and shared dispositive power. Control is exercised through investment funds managed by Sirenia Capital Management LP.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 08:36 AM Accepted by SEC EDGAR 08/14/2026 - 08:36 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Tonix Pharmaceuticals Holding Corp.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

890260839

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 890260839

1

Names of Reporting Persons

Sirenia Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 814,801.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 814,801.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

814,801.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: Includes 615,025 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.

SCHEDULE 13G

CUSIP Number(s): 890260839

1

Names of Reporting Persons

Alex Silverstein

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 814,801.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 814,801.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

814,801.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 615,025 shares of Common Stock issuable upon exercise of warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tonix Pharmaceuticals Holding Corp.
(b)	Address of issuer's principal executive offices: 200 Connell Drive, Suite 3100, Berkeley Heights, NJ 07922
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Sirenia Capital Management LP ("Sirenia") with respect to the common stock, par value $0.001 per share ("Common Stock"), of Tonix Pharmaceuticals Holding Corp. (the "Issuer") held by, and issuable upon exercise of warrants held by, investment funds it manages (the "Sirenia Funds"); and (ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Stock held by, and issuable upon exercise of warrants held by, the Sirenia Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.
(c)	Citizenship: Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 890260839
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 15,940,801 shares of Common Stock outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 11, 2026, and assumes the exercise of the warrants held by the Sirenia Funds.
(b)	Percent of class: 4.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Item 2(a) and Item 3.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sirenia Capital Management LP

Signature:	/s/ Kolby Loft
Name/Title:	Kolby Loft, General Counsel & Chief Compliance Officer
Date:	08/14/2026

Alex Silverstein

Signature:	/s/ Alex Silverstein
Name/Title:	Alex Silverstein, individually
Date:	08/14/2026